A synthesized gamma distribution-based patient-specific VMAT QA using a generative adversarial network
Takaaki Matsuura1,2, Daisuke Kawahara2, Akito Saito3
1Hiroshima High-Precision Radiotherapy Cancer Center, Hiroshima, Japan.
Background:
Artificial intelligence (AI)-based gamma passing rate (GPR) prediction has been proposed as a time-efficient virtual patient-specific QA method for the delivery of volumetric modulation arc therapy (VMAT). However, there is a limitation that the GPR value loses the locational information of dose accuracy.
Purpose:
The objective was to predict the failing points in the gamma distribution and the GPR using a synthesized gamma distribution of VMAT QA with a deep convolutional generative adversarial network (GAN).
Methods:
The fluence maps of 270 VMAT beams for prostate cancer were measured using an electronic portal imaging device and analyzed using gamma evaluation with 3%/2-mm, 2%/1-mm, 1%/1-mm, and 1%/0.5-mm tolerances. The 270 gamma distributions were divided into two datasets: 240 training datasets for creating a model and 30 test datasets for evaluation. The image prediction network for the fluence maps calculated by the treatment planning system (TPS) to the gamma distributions was created using a GAN. The sensitivity, specificity, and accuracy of detecting failing points were evaluated using measured and synthesized gamma distributions. In addition, the difference between measured GPR (mGPR) and predicted GPR (pGPR) values calculated from the synthesized gamma distributions was evaluated.
Results:
The root mean squared errors between mGPR and pGPR were 1.0%, 2.1%, 3.5%, and 3.6% for the 3%/2-mm, 2%/1-mm, 1%/1-mm, and 1%/0.5-mm tolerances, respectively. The accuracies for detecting failing points were 98.9%, 96.9%, 94.7%, and 93.7% for 3%/2-mm, 2%/1-mm, 1%/1-mm, and 1%/0.5-mm tolerances, respectively. The sensitivity and specificity were the highest for 1%/0.5-mm and 3%/2-mm tolerances, which were 82.7% and 99.6%, respectively.
Conclusions:
We developed a novel system using a GAN to generate a synthesized gamma distribution-based patient-specific VMAT QA. The system is promising from the point of view of quality assurance in radiotherapy because it shows high performance and can detect failing points.
